Cargando…
LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
BACKGROUND: Sotrovimab, a monoclonal antibody with efficacy against SARS-CoV-2 including certain Omicron variants, has been used in treatment of mild-moderate COVID-19. Limited data exists regarding its use in pregnant women. METHODS: Electronic medical record review of pregnant COVID-19 patients tr...
Autores principales: | Tuan, Jessica, Sharma, Manas, Kayani, Jehanzeb, Davis, Matthew W, McManus, Dayna, Topal, Jeffrey E, Ogbuagu, Onyema |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752459/ http://dx.doi.org/10.1093/ofid/ofac492.1887 |
Ejemplares similares
-
Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023) -
COLLABORATION AGREEMENT NO. K1577
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2008) -
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022) -
Cantabile and presto : For flute and piano /
por: Enescu, Georges -
Learning and Operating Presto
por: Bharathan, Vivek
Publicado: (2021)